Patents Examined by Meghan Finn
-
Patent number: 7923447Abstract: Disclosed herein are parenteral solutions containing 7-halo-1,2,3,4-tetrahydro-3-aryl-6-quinazoline sulfonamide in N,N-dimethylactamide, polyethylene glycol and D5W useful in the treatment of hypertension, heart failure and renal disease leading to edematous states. Also disclosed are methods for preparing such solutions.Type: GrantFiled: March 17, 2008Date of Patent: April 12, 2011Assignee: Academic Pharmaceuticals IncorporatedInventors: John C. Somberg, Vasant V. Ranade
-
Patent number: 7910626Abstract: The invention relates to the use of a sphingosine-1-phosphate receptor agonist in the treatment of heart diseases.Type: GrantFiled: October 2, 2008Date of Patent: March 22, 2011Assignee: Novartis AGInventors: Volker Brinkmann, Gilles Feutren, Robert Paul Hof
-
Patent number: 7875624Abstract: Methods of using compounds having Structure I or the salts or tautomers of the compounds in the treatment of disorders relating to cell adhesion and metastatic processes are presented herein.Type: GrantFiled: February 18, 2005Date of Patent: January 25, 2011Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Carla Heise, Sang H. Lee
-
Patent number: 7846968Abstract: This invention is directed to methods for controlling the duration of the depolarization and repolarization of the cardiac ventricle and therefore the QT interval, in therapeutically useful ways in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II), or a pharmaceutically acceptable salt or ester thereof: wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with phenyl, wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 alkoxy, amino, nitro and cyano.Type: GrantFiled: January 11, 2006Date of Patent: December 7, 2010Assignee: Janssen Pharmaceutica, N.V.Inventors: Shuchean Chien, Gerald Novak, Luc Truyen, Eric Yuen
-
Patent number: 7846963Abstract: The present invention is related to new 2-oxo-cyclic compound the process for preparing them and a pharmaceutical composition comprising the same. The present invention provides a pharmaceutical composition for preventing and treating the inflammatory disease comprising the pain or inflammation caused by rheumatic disease, for example, rheumatoid arthritis, spondyloarthopathies, gout, osteoarthritis, systemic lupus erythematosus and juvenile arthritis, and inflammatory syndrome for example, from myositis, gingivitis, synovitis, ankylosing spondylitis, burstitis, burns and scar, inflammatory Crohn's disease, Types I diabetes. therefore, it can be used as the therapeutics for treating and preventing inflammatory diseases.Type: GrantFiled: May 17, 2004Date of Patent: December 7, 2010Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Yung Hee Kho, Gyoon Hee Han, Ho Jae Lee, Bum Woo Park, Hyo Kon Chun, Hwan Mook Kim, Song Kyu Park, Sang Bae Han, Dong Kyu Ryu, Tae Gyu Chun, Jin Ha Lee, Chang Woo Lee, Ki Hoon Lee, Hee Yoon Lee
-
Patent number: 7847109Abstract: Variously substituted carbonate and carbamate derivatives of triptolide compounds have good aqueous solubility and convert to biologically active compounds in vivo, at a rate which can be modulated by varying the substitution on the prodrug. The prodrugs are useful as immunosuppressive, anti-inflammatory and anticancer agents.Type: GrantFiled: May 29, 2003Date of Patent: December 7, 2010Assignee: Pharmagenesis, Inc.Inventors: Dongcheng Dai, John H. Musser, Edwin S. Lennox
-
Patent number: 7838562Abstract: Agonist of vascular endothelial sphingosine-1-phosphate receptors are described. Compounds such as FTY720 can be phosphorylated by sphingosine kinase-2 into the phosphorylated forms which serve as sphingosine-1-phosphate receptor agonists. The vascular endothelial sphingosine-1-phosphate receptor agonists are employed in methods of treating a mammal for vascular permeability disorders and unwanted vascular endothelial cell apoptosis, and for the growth of new blood vessels. The sphingosine-1-phosphate receptor agonists can be used for the manufacture of a medicament for treating vascular permeability disorders and unwanted vascular endothelial cell apoptosis, and for the growth of new blood vessels.Type: GrantFiled: June 18, 2004Date of Patent: November 23, 2010Assignee: University of ConnecticutInventors: Timothy Hla, Teresa Sanchez, Kevin Patrick Claffey, Ji-Hye Paik
-
Patent number: 7803843Abstract: The subject invention provides materials and methods for improving alcohol metabolism in animals. In a preferred embodiment, the invention provides methods for increasing the ability of people to consume alcohol while reducing hangovers or other effects of intoxication. Specifically exemplified herein is the use of a cysteamine compound to reduce the adverse effects of alcohol consumption. For example, the undesirable and unpleasant symptoms association with hangovers can be reduced through consumption, according to the subject invention, of cysteamine hydrochloride.Type: GrantFiled: November 5, 2004Date of Patent: September 28, 2010Assignee: Omega Bio-Pharma (I.P.1) Ltd.Inventors: Wen Qin Tang, Francis Chi
-
Patent number: 7745475Abstract: Compounds of Formula (I) wherein: R1 is hydroxymethyl; R2 is selected from —C(O)NR4R5, SO2NR4R5, S(O)pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R4 is selected from for example hydrogen, optionally substituted (1-4C)alkyl and HET-2; R5 is hydrogen or (1-4C)alkyl; or R4 and R5 together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is for example an optionally substituted N-linked, 4, 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring; p is (independently at each occurrence) 0, 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, then n is 1 or 2; or a salt, pro drug or solvate thereof, are described.Type: GrantFiled: June 1, 2005Date of Patent: June 29, 2010Assignee: AstraZeneca ABInventors: Craig Johnstone, Darren McKerrecher, Kurt Gordon Pike, Michael James Waring
-
Patent number: 7723358Abstract: The present invention relates to derivatives of aroyl-O-piperidine structure of the general formula (I): in which R1, R2, R3 and R4 are as defined in the description. Application of the compounds of the formula (I) to the treatment of hyper-triglyceridaemia, hypercholesterolaemia and dyslipidaemia, and to the prevention or treatment of obesity.Type: GrantFiled: May 19, 2005Date of Patent: May 25, 2010Assignee: Merck Patent GmbHInventors: Philippe Guedat, Francois Collonges, Olivier Chevreuil, Hervé Dumas, Marie Noelle Denault, Stéphane Yvon, Peter Kane, Julia Lainton, Avril Robertson, Bernd Wendt
-
Patent number: 7723376Abstract: The present invention is related to novel use of 2-oxo-heterocyclic compounds having anticancer activity and the process for preparing them and a pharmaceutical composition comprising the same.Type: GrantFiled: July 15, 2004Date of Patent: May 25, 2010Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Hwan Mook Kim, Gyoon Hee Han, Song Kyu Park, Chang Woo Lee, Sang Bae Han, Ki Hoon Lee, Yung Hee Kho, Jin Hyuk Yang, Bum Woo Park, Hyang Woo Lee, Jeung Whan Han, Dong Kyu Ryu, Jin Ha Lee, Tae Gyu Chun, Yong Kee Kim, Hee Yoon Lee, Bong Yong Lee, Jeom Yong Kim, Ji Duck Kim, Kyunga Yu, Sun Young Kim
-
Patent number: 7700084Abstract: The present invention relates to a mixture, having a skin-tightening effect, which is made up of: 10 to 80% by weight of a polysaccharide, preferably of an alginate, having a molecular weight of less than 600,000 Daltons, preferably less than 400,000 Daltons and more preferably less than 200,000 Daltons, 15 to 75% by weight of a polyhydroxylated agent selected from sugars and their derivatives, particularly sugar esters and sugar ethers, preferably sorbitol, 3 to 15% by weight of poly(vinyl alcohol) or polyvinylpyrrolidone, and 0 to 25% by weight of cellulose or of a derivative of cellulose, such as carboxymethylcellulose or hydroxymethylcellulose. The present invention also relates to cosmetic compositions which contain this mixture. These cosmetic compositions enable a mechanical smoothing of the surface of the skin to be obtained progressively with great comfort of use and enables a good fixing of make-up products.Type: GrantFiled: August 27, 2002Date of Patent: April 20, 2010Assignee: LVMH RechercheInventors: Hervé Delage-Grouiller, Brigitte Noe, Christian Mahe
-
Patent number: 7687493Abstract: The present invention relates to a novel method for the preparation of azetidine derivatives such as N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-quinol-6-ylmethylsulfonamide and the dihydrochloride thereof and N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide.Type: GrantFiled: March 22, 2007Date of Patent: March 30, 2010Assignee: Aventis Pharma SAInventors: Stephane Mutti, Michel Lavigne, Luc Grondard, Joel Malpart, Joerg Rieke-Zapp, Veronique Crocq-Stuerga
-
Patent number: 7652139Abstract: The invention relates to methyl(+)-(S)-?-(2-chlorophenyl)-6,7-dihydrothieno[3,2-C]pyridine-5(4H) acetate naphthalene-1,5-disulfonate or a polymorphic form and/or a hydrate and/or a solvate thereof, to pharmaceutical compositions containing the same, and to the method of use thereof for inhibiting platelet aggregation.Type: GrantFiled: October 19, 2006Date of Patent: January 26, 2010Assignee: sanofi-aventisInventors: Keith Richard Lorimer, Alicia Tee Fuay Ng
-
Patent number: 7612082Abstract: Disclosed herein are methods and compositions related to compound 1 or compound 2 or pharmaceutically acceptable salts, or prodrugs thereof, which are antagonists of a prostaglandin EP4 receptor, or are prostaglandin EP4 antagonists.Type: GrantFiled: October 28, 2004Date of Patent: November 3, 2009Assignee: Allergan, Inc.Inventors: Larry A. Wheeler, Michael E. Garst, Yanbin Liang, David F. Woodward, Achim H.-P. Krauss, Robert M. Burk, Yariv Donde, Mark Holoboski, David W. Old, June Chen
-
Patent number: 7612084Abstract: The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.Type: GrantFiled: March 19, 2007Date of Patent: November 3, 2009Assignee: Pfizer IncInventors: Kim James, Lyn Howard Jones, David Anthony Price
-
Patent number: 7601863Abstract: The invention describes the use of PPAR agonists of the formulae (I) or (II) for the treatment of congestive heart failure (CHF).Type: GrantFiled: June 14, 2007Date of Patent: October 13, 2009Assignee: sanofi-aventis Deutschland GmbHInventors: Wolfgang Linz, Stefan Schaefer, Eugen Falk, Hans-Ludwig Schaefer
-
Patent number: 7528124Abstract: A 1,3-dihydro-2H-indol-2-one derivative expressed by Formula 1 (wherein R1 is a halogen atom, a C1 to C4 alkyl group, etc., and R2 is a hydrogen atom, a halogen atom, etc., or R2 is in the 6-position of the indol-2-one and R1 and R2 join together to form a C3 to C6 alkylene group, R3 is a halogen atom, a hydroxyl group, etc., and R4 is a hydrogen atom, a halogen atom, a C1 to C4 alkyl group, etc., or R4 is in the 3-position of the phenyl and R3 and R4 join together to form a methylenedioxy group, R5 is a hydrogen atom or a fluorine atom, R6 is an ethylamino group, a dimethylamino group, etc., R7 is a C1 to C4 alkoxy group, and R8 is a C1 to C4 alkoxy group), or a pharmaceutically acceptable salt of this derivative. This is a novel compound that has antagonistic activity against an aruginine-vasopressin V1b receptor.Type: GrantFiled: August 27, 2004Date of Patent: May 5, 2009Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Toshihito Kumagai, Takeshi Kuwada, Tsuyoshi Shibata, Masato Hayashi, Yuri Fujisawa, Yoshinori Sekiguchi
-
Patent number: 7361687Abstract: The present invention relates to novel arylsulphonamide compounds, defined by formula I and the description, as well as their method of preparation and their therapeutic useType: GrantFiled: June 12, 2003Date of Patent: April 22, 2008Assignee: Laboratoires Fournier SAInventors: Martine Barth, Michel Bondoux, Pierre Dodey, Christine Massardier, Jean-Michel Luccarini